Investments
141Portfolio Exits
58Funds
19Partners & Customers
1Service Providers
2About Ampersand Capital Partners
Ampersand Capital Partners is a middle-market private equity firm focused on investments in the healthcare and industrial sectors. The company was founded in 1988 and is based in Wellesley, Massachusetts.
Want to inform investors similar to Ampersand Capital Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Ampersand Capital Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Ampersand Capital Partners in 2 Expert Collections, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Synthetic Biology
382 items
Latest Ampersand Capital Partners News
Sep 12, 2023
News provided by Share this article New Brand Reflects Vast Experience and Commitment to Continued Innovation in the Medical Technology Industry MOONACHIE, N.J. and LENEXA, Kan., Sept. 12, 2023 /PRNewswire/ -- Sterling Medical Devices and RBC Medical Innovations announced today the rebranding of the combined company as Vantage MedTech. Leveraging decades of industry experience and the specialized expertise of more than 150 medical device engineers, Vantage MedTech is poised to continue providing complete life cycle solutions to medical technology innovators, from concept through to product realization. The Company's integrated capabilities include full-systems development utilizing its software, industrial, mechanical and electrical engineering expertise, clinical and commercial scale manufacturing, and regulatory strategy consulting, all supported by the Company's robust quality systems. "We are thrilled to announce our new brand at this exciting juncture in our company's evolution", said David Montecalvo, CEO. "Vantage offers the MedTech industry a wide range of integrated engineering and technical expertise, resulting in faster time-to-market results for our clients. We are committed to partnering with our clients to accelerate commercialization of their life-changing medical devices and are dedicated to providing these solutions with the highest integrity, quality standards and excellence." About Vantage MedTech Vantage MedTech provides comprehensive design and manufacturing services, supporting the advancement of medical technologies from concept through to product realization. Partnering with the world's most innovative MedTech start-ups and large OEMs, we offer feasibility support, product development and prototyping, clinical and commercial manufacturing, and after-market services to support every phase of the product life cycle. Our clients can leverage our proprietary Advantage Platforms ™, accelerating product development timelines. Our manufacturing approach is structured to serve the changing needs of our clients, supporting small-quantity clinical or First-in-Human builds and can scale to accommodate full launch quantities. Vantage MedTech has offices in Moonachie, New Jersey and Lenexa, Kansas. Additional information is available at available at VantageMedTech.com , SterlingMedicalDevices.com , and RBCCorp.com . About Ampersand Capital Partners Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn . SOURCE Vantage MedTech
Ampersand Capital Partners Investments
141 Investments
Ampersand Capital Partners has made 141 investments. Their latest investment was in Vernal Biosciences as part of their Series B on June 6, 2023.
Ampersand Capital Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/27/2023 | Series B | Vernal Biosciences | $20M | No | 2 | |
6/12/2023 | Series B | NanoImaging Services | Yes | 4 | ||
5/2/2023 | Recap | P95 | Yes | 1 | ||
6/23/2022 | Private Equity | |||||
6/7/2022 | Series C - II |
Date | 6/27/2023 | 6/12/2023 | 5/2/2023 | 6/23/2022 | 6/7/2022 |
|---|---|---|---|---|---|
Round | Series B | Series B | Recap | Private Equity | Series C - II |
Company | Vernal Biosciences | NanoImaging Services | P95 | ||
Amount | $20M | ||||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 4 | 1 |
Ampersand Capital Partners Portfolio Exits
58 Portfolio Exits
Ampersand Capital Partners has 58 portfolio exits. Their latest portfolio exit was GenDx on August 17, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/17/2022 | Acquired | 11 | |||
2/18/2022 | Acquired | 2 | |||
2/18/2022 | Acquired | 3 | |||
Date | 8/17/2022 | 2/18/2022 | 2/18/2022 | ||
|---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 11 | 2 | 3 |
Ampersand Capital Partners Acquisitions
27 Acquisitions
Ampersand Capital Partners acquired 27 companies. Their latest acquisition was iuvo BioScience on September 28, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/28/2022 | Acq - Fin | 1 | ||||
8/30/2022 | Acq - Fin | 2 | ||||
8/25/2022 | Acq - Fin | 1 | ||||
7/1/2021 | ||||||
9/21/2020 |
Date | 9/28/2022 | 8/30/2022 | 8/25/2022 | 7/1/2021 | 9/21/2020 |
|---|---|---|---|---|---|
Investment Stage | |||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acq - Fin | Acq - Fin | Acq - Fin | ||
Sources | 1 | 2 | 1 |
Ampersand Capital Partners Fund History
19 Fund Histories
Ampersand Capital Partners has 19 funds, including Ampersand 2022.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
9/2/2022 | Ampersand 2022 | $1,200M | 1 | ||
11/19/2020 | Ampersand Continuation Fund | $670M | 2 | ||
3/31/2020 | Ampersand 2020 | Multi-Stage Venture Capital | Open | $690M | 3 |
3/19/2018 | Ampersand Capital Partners Fund I | ||||
5/29/2015 | Ampersand 2014 LP |
Closing Date | 9/2/2022 | 11/19/2020 | 3/31/2020 | 3/19/2018 | 5/29/2015 |
|---|---|---|---|---|---|
Fund | Ampersand 2022 | Ampersand Continuation Fund | Ampersand 2020 | Ampersand Capital Partners Fund I | Ampersand 2014 LP |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Open | ||||
Amount | $1,200M | $670M | $690M | ||
Sources | 1 | 2 | 3 |
Ampersand Capital Partners Partners & Customers
1 Partners and customers
Ampersand Capital Partners has 1 strategic partners and customers. Ampersand Capital Partners recently partnered with GenDx on May 5, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/6/2019 | Partner | Netherlands | The partnership between Ampersand Capital Partners and GenDx aims to foster sustainable growth , both organically and through M&A activities in the molecular diagnostic products and services market . | 5 |
Date | 5/6/2019 |
|---|---|
Type | Partner |
Business Partner | |
Country | Netherlands |
News Snippet | The partnership between Ampersand Capital Partners and GenDx aims to foster sustainable growth , both organically and through M&A activities in the molecular diagnostic products and services market . |
Sources | 5 |
Ampersand Capital Partners Service Providers
2 Service Providers
Ampersand Capital Partners has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | |||
Service Provider | ||
|---|---|---|
Associated Rounds | ||
Provider Type | Counsel | |
Service Type |
Partnership data by VentureSource
Ampersand Capital Partners Team
8 Team Members
Ampersand Capital Partners has 8 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Richard A. Charpie | Founder | Current | |
Name | Richard A. Charpie | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
